{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:42:05Z","timestamp":1790037725502,"version":"4.0.1"},"reference-count":211,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":1680,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2007,6]]},"abstract":"<jats:p>Tipranavir is a nonpeptidic protease inhibitor that has activity against human immunodeficiency virus strains resistant to multiple protease inhibitors. Tipranavir 500 mg is coadministered with ritonavir 200 mg. Tipranavir is metabolized by cytochrome P450 (CYP) 3A and, when combined with ritonavir in vitro, causes inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A in addition to induction of glucuronidase and the drug transporter P\u2010glycoprotein. As a result, drug\u2010drug interactions between tipranavir\u2010ritonavir and other coadministered drugs are a concern. In addition to interactions with other antiretrovirals, tipranavir\u2010ritonavir interactions with antifungals, antimycobacterials, oral contraceptives, statins, and antidiarrheals have been specifically evaluated. For other drugs such as antiarrhythmics, antihistamines, ergot derivatives, selective serotonin receptor agonists (or triptans), gastrointestinal motility agents, erectile dysfunction agents, and calcium channel blockers, interactions can be predicted based on studies with other ritonavir\u2010boosted protease inhibitors and what is known about tipranavir\u2010ritonavir CYP and P\u2010glycoprotein utilization. The highly complex nature of drug interactions dictates that cautious prescribing should occur with narrow\u2013therapeutic\u2010index drugs that have not been specifically studied. Thus, the known interaction potential of tipranavir\u2010ritonavir is reported, and in vitro and in vivo data are provided to assist clinicians in predicting interactions not yet studied. As more clinical interaction data are generated, better insight will be gained into the specific mechanisms of interactions with tipranavir\u2010ritonavir.<\/jats:p>","DOI":"10.1592\/phco.27.6.888","type":"journal-article","created":{"date-parts":[[2007,6,4]],"date-time":"2007-06-04T07:29:12Z","timestamp":1180942152000},"page":"888-909","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Mechanisms of Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Ritonavir\u2010Enhanced Tipranavir"],"prefix":"10.1002","volume":"27","author":[{"given":"Manoli","family":"Vourvahis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela D. M.","family":"Kashuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"SaxPE.FDA approval: tipranavir [letter].AIDS Clin Care2005;3."},{"key":"e_1_2_1_3_2","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc.Tipranavir. Antiviral drugs advisory committee (AVDAC) briefing document NDA 21\u2013814. Ridgefield CT;2005."},{"key":"e_1_2_1_4_2","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc.Aptivus (tipranavir) package insert. Ridgefield CT;2005."},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200309011-00014"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.5.1328-1332.2000"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200009080-00009"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm9802158"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200404010-00007"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565120-00005"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.005447"},{"key":"e_1_2_1_12_2","unstructured":"Abbott Laboratories.Kaletra (lopinavir\u2010ritonavir) package insert. North Chicago IL;2005."},{"key":"e_1_2_1_13_2","unstructured":"vanHeeswijkR SaboJP MacGregorTR et al.The effect of tipranavir\/ritonavir 500 mg\/200 mg bid (TPV\/r) on the pharmacokinetics of fluconazole in healthy volunteers [abstract]. Poster presentation at the 5th international workshop on clinical pharmacology in HIV therapy Rome Italy April 13 2004: abstract 4.8."},{"key":"e_1_2_1_14_2","volume-title":"The effect of tipranavir\/ritonavir 500\/200 mg bid (TPV\/r) on the pharmacokinetics (PK) of clarithromycin (CLR) in healthy volunteers [abstract]","author":"Heeswijk R","year":"2004"},{"key":"e_1_2_1_15_2","volume-title":"The pharmacokinetic (PK) interaction between single\u2010dose rifabutin (RFB) and steady\u2010state tipranavir\/ritonavir 500\/200 mg bid (TPV\/r) in healthy volunteers [abstract]","author":"Heeswijk R","year":"2004"},{"key":"e_1_2_1_16_2","unstructured":"vanHeeswijkR SaboJP CooperC et al.The pharmacokinetic interactions between tipranavir\/ritonavir 500 mg\/200 mg bid (TPV\/r) and atorvastatin antacid and CYP3A4 in healthy volunteers [abstract]. Poster presentation at the 5th international workshop on clinical pharmacology in HIV therapy Rome Italy April 13 2004: abstract 5.2."},{"key":"e_1_2_1_17_2","unstructured":"VourvahisM DumondJ PattersonK et al.Effects of tipranavir\/ritonavir (TPV\/r) on the activity of hepatic and intestinal cytochrome P450 3A4\/5 and P\u2010glycoprotein (Pgp): implications for drug interactions [abstract]. Presented at the 14th conference on retroviruses and opportunistic infections Los Angeles February 2528 2007: abstract 563."},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.12.4903-4910.2005"},{"key":"e_1_2_1_19_2","unstructured":"SaboJP ElgadiM WruckJ et al.The pharmacokinetic interaction between atazanavir\/ritonavir (ATV\/r) and steady\u2010state tipranavir\/ritonavir (TPV\/r) in healthy volunteers [abstract]. Presented at the 7th international workshop on clinical pharmacology of HIV therapy Lisbon Portugal April 2022 2006: abstract 41."},{"key":"e_1_2_1_20_2","unstructured":"RoszkoPJ CurryK BrazinaB et al.Standard doses of efavirenz (EFV) zidovudine (ZDV) tenofovir (TDF) and didanosine (ddI) may be given with tipranavir\/ritonavir (TPV\/r) [abstract]. Presented at the 2nd International AIDS Society conference on HIV pathogenesis and treatment Paris France July 1316 2003: abstract 865."},{"key":"e_1_2_1_21_2","unstructured":"SchollerM KraftM HoetelmansR et al.Significant decrease in TMC125 exposures when co\u2010administered with tipranavir (boosted with ritonavir) in healthy subjects [abstract]. Presented at the 13th conference on retroviruses and opportunistic infections Denver CO February 59 2006: abstract 583."},{"key":"e_1_2_1_22_2","volume-title":"Effect of tipranavir + ritonavir (TPV + RTV) on pharmacokinetics of MK\u20100518 [abstract]","author":"Wenning LA","year":"2006"},{"key":"e_1_2_1_23_2","unstructured":"AbelS Taylor\u2010WorthR RidgwayC WeissgerberG KraftM.Effect of boosted tipranavir on the pharmacokinetics of maraviroc (UK427 857) in healthy volunteers [abstract]. Presented at the 7th international workshop on clinical pharmacology of HIV therapy Lisbon Portugal April 2022 2006: abstract 77."},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/381783"},{"key":"e_1_2_1_25_2","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc.Aptivus: drug interactions. Ridgefield CT;2005."},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-199807000-00039"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280100277"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02208.x"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.160-165.2002"},{"key":"e_1_2_1_30_2","unstructured":"McCallisterS SaboJP MayersDL GalitzL.An open\u2010label steady\u2010state investigation of the pharmacokinetics (PK) of tipranavir (TPV) and ritonavir (RTV) and their effects on cytochrome P\u2010450 (3A4) activity in normal healthy volunteers (BI 1182.5) [abstract]. Poster presentation at the 9th conference on retroviruses and opportunistic infections Seattle WA February 2428 2002: abstract 434\u2010W."},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1089\/088922203322493148"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1086\/382675"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161001-00003"},{"key":"e_1_2_1_34_2","unstructured":"Pfizer Inc.Vfend (voriconazole) package insert. New York NY;2006."},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.5.540"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.02001.x"},{"key":"e_1_2_1_37_2","unstructured":"LiuP FosterG LabadieR AllisonMJ SharmaA.Pharmacokinetic interaction between voriconazole and ritonavir at steady state in healthy subjects [abstract]. Presented at the annual meeting of the American Society for Clinical Pharmacology and Therapeutics Orlando Florida March 26 2005: abstract PI\u2010123."},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92967-3"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-829505"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1310\/AQML-UABK-5LLB-E615"},{"issue":"15","key":"e_1_2_1_41_2","first-page":"1","article-title":"Treating opportunistic infections among HIV\u2010infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America","volume":"53","author":"Benson CA","year":"2004","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1086\/380794"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.128387"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1310\/RRX7-49ME-27V7-MWWV"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608083350603"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608083350602"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.125559"},{"key":"e_1_2_1_48_2","unstructured":"Abbott Laboratories.Biaxin (clarithromycin) package insert. North Chicago IL;2006."},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:PHAM.0000033017.52484.81"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70138-4"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00749.x"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.13.2050"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(96)00742-4"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1086\/378131"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200208150-00012"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200203080-00008"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-004-3136-7"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200209270-00024"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80336-3"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000174458.86121.43"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000216371.76689.63"},{"key":"e_1_2_1_62_2","unstructured":"GoebelFD SaboJP MacGregorTR MayersDL McCallisterS.Pharmacokinetic drug interaction screen of three doses of tipranavir\/ritonavir in HIV\u2010infected patients on stable highly active antiretroviral therapy [abstract]. Presented at HIV DART frontiers in drug development for antiretroviral therapies Naples FL December 1519 2002."},{"key":"e_1_2_1_63_2","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1128\/AAC.42.7.1592","article-title":"Glucuronidation of 3\u2032\u2010azido\u20103\u2032\u2010deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid","volume":"42","author":"Trapnell CB","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_64_2","unstructured":"Agouron Pharmaceuticals Inc.Viracept (nelfinavir mesylate) package insert. La Jolla CA;2006."},{"key":"e_1_2_1_65_2","unstructured":"GlaxoSmithKline Pharmaceuticals.Ziagen (abacavir) prescribing information. Research Triangle Park NC;2006."},{"key":"e_1_2_1_66_2","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc.Viramune (nevirapine) package insert. Ridgefield CT;2005."},{"key":"e_1_2_1_67_2","unstructured":"Bristol\u2010Meyers Squibb Company.Sustiva (efavirenz) package insert. Princeton NJ;2005."},{"key":"e_1_2_1_68_2","unstructured":"SaboJP MacGregorT LamsonMJ BaldwinJ BorinM.Pharmacokinetics of tipranavir and nevirapine: a pharmacokinetic interaction study in healthy volunteers [abstract]. Presented at HIV DART frontiers in drug development for antiretroviral therapies Isla Verde Puerto Rico December 1721 2000: abstract 103."},{"key":"e_1_2_1_69_2","volume-title":"Drug interactions with TMC125, a potent next generation NNRTI [abstract]","author":"Baede P","year":"2002"},{"key":"e_1_2_1_70_2","volume-title":"TMC125 does not alter lopinavir\/ritonavir (LPV\/RTV) pharmacokinetics in healthy volunteers [abstract]","author":"Piscitelli S","year":"2002"},{"key":"e_1_2_1_71_2","unstructured":"BoffitoM WinstonA FletcherC et al.Pharmacokinetics and antiretroviral response to TMC\u2010114\/r and TMC125 combination in patients with high level viral resistance [abstract]. Presented at the 13th conference on retroviruses and opportunistic infections Denver CO February 59 2006: abstract 767c."},{"key":"e_1_2_1_72_2","doi-asserted-by":"crossref","unstructured":"DupuisML CianfrigliaM CostiR et al.HIV\u20101 integrase inhibitors are potent substrates for the MDR1 multidrug transporter [abstract]. Presented at the 13th conference on retroviruses and opportunistic infections Denver CO February 59 2006: abstract 566.","DOI":"10.1186\/1742-4690-4-17"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.13.1473"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90972-F"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0133-z"},{"key":"e_1_2_1_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/0160-5402(87)90069-6"},{"key":"e_1_2_1_77_2","volume-title":"Guidelines for the use of antiretroviral agents in HIV\u2010infected adults and adolescents","author":"Panel on Clinical Practices for Treatment of HIV Infection Convened by the Department of Health and Human Services.","year":"2006"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006199-200107000-00004"},{"key":"e_1_2_1_79_2","unstructured":"HawkinsT.Nelfinavir\u2010induced diarrhea is manageable with nonprescription medications [abstract]. Presented at the international AIDS conference Geneva Switzerland June 28July 3 1998: abstract 12401."},{"key":"e_1_2_1_80_2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0002-8223(21)01943-X","article-title":"Effect of fiber supplements on the apparent absorption of pharmacological doses of riboflavin","volume":"88","author":"Roe DA","year":"1988","journal-title":"J Am Diet Assoc"},{"key":"e_1_2_1_81_2","unstructured":"RazzecaK OdenheimerS DavisN LandeckK.The treatment of nelfinavir\u2010induced diarrhea [abstract]. Presented at the international AIDS conference Geneva Switzerland June 28July 3 1998: abstract 12383."},{"key":"e_1_2_1_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17950-1"},{"key":"e_1_2_1_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(93)90523-6"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.00556.x"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.26"},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.1080\/00498250500202056"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199303000-00024"},{"key":"e_1_2_1_88_2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0090-9556(25)07372-6","article-title":"Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data","volume":"24","author":"Walker DK","year":"1996","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"e_1_2_1_89_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0002-9149(96)00560-7","article-title":"Electrophysiology and pharmacology of ibutilide","volume":"78","author":"Naccarelli GV","year":"1996","journal-title":"Am J Cardiol"},{"key":"e_1_2_1_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(92)91593-F"},{"key":"e_1_2_1_91_2","doi-asserted-by":"publisher","DOI":"10.1053\/cp.1999.v66.a101462"},{"key":"e_1_2_1_92_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199427010-00001"},{"key":"e_1_2_1_93_2","first-page":"95","volume-title":"Med Lett Drugs Ther","author":"Abramowicz M","year":"1996"},{"key":"e_1_2_1_94_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2002.00422.x"},{"key":"e_1_2_1_95_2","doi-asserted-by":"publisher","DOI":"10.1086\/376636"},{"key":"e_1_2_1_96_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140030-00004"},{"key":"e_1_2_1_97_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.106292"},{"key":"e_1_2_1_98_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430070125014"},{"key":"e_1_2_1_99_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.3.336"},{"key":"e_1_2_1_100_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.140.9.1183"},{"key":"e_1_2_1_101_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-198403000-00007"},{"key":"e_1_2_1_102_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200006000-00005"},{"key":"e_1_2_1_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70117-7"},{"key":"e_1_2_1_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(00)00123-0"},{"key":"e_1_2_1_105_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.3.243"},{"key":"e_1_2_1_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.07.007"},{"key":"e_1_2_1_107_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02507.x"},{"key":"e_1_2_1_108_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03189827"},{"key":"e_1_2_1_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90179-4"},{"key":"e_1_2_1_110_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.184"},{"key":"e_1_2_1_111_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1993.25"},{"key":"e_1_2_1_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90162-9b"},{"key":"e_1_2_1_113_2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0022-3565(25)12284-2","article-title":"Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole","volume":"276","author":"Moltke LL","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_114_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200006010-00007"},{"key":"e_1_2_1_115_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199908000-00001"},{"key":"e_1_2_1_116_2","unstructured":"Roche Laboratories Inc.Klonopin (clonazepam) package insert. Nutley NJ;2001."},{"key":"e_1_2_1_117_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.105757"},{"key":"e_1_2_1_118_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00614203"},{"key":"e_1_2_1_119_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840030219"},{"key":"e_1_2_1_120_2","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1128\/AAC.42.7.1788","article-title":"Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus\u2010infected patients","volume":"42","author":"Cato A","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_121_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199811010-00008"},{"key":"e_1_2_1_122_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00953.x"},{"key":"e_1_2_1_123_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200060020-00014"},{"key":"e_1_2_1_124_2","doi-asserted-by":"publisher","DOI":"10.1080\/00498250210158221"},{"key":"e_1_2_1_125_2","doi-asserted-by":"publisher","DOI":"10.1080\/004982598239452"},{"key":"e_1_2_1_126_2","unstructured":"Wyeth Pharmaceuticals Inc.Sonata (zaleplon) package insert. Philadelphia PA;2004."},{"key":"e_1_2_1_127_2","unstructured":"Sepracor Inc.Lunesta (eszopiclone) package insert. Marlborough MA;2005."},{"key":"e_1_2_1_128_2","first-page":"572","article-title":"Trazodone is metabolized to m\u2010chlorophenylpiperazine by CYP3A4 from human sources","volume":"26","author":"Rotzinger S","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_129_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/163.3.454"},{"key":"e_1_2_1_130_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/163.5.1138"},{"key":"e_1_2_1_131_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/17.1.117"},{"key":"e_1_2_1_132_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/163.2.414"},{"key":"e_1_2_1_133_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2005.00095.x"},{"key":"e_1_2_1_134_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.43.5.424"},{"key":"e_1_2_1_135_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20165"},{"key":"e_1_2_1_136_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D076"},{"key":"e_1_2_1_137_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000112935.43362.37"},{"key":"e_1_2_1_138_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.001651"},{"key":"e_1_2_1_139_2","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200014060-00002"},{"key":"e_1_2_1_140_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1998.tb03343.x"},{"key":"e_1_2_1_141_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000187444.38461.70"},{"key":"e_1_2_1_142_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000242929.95258.69"},{"key":"e_1_2_1_143_2","unstructured":"GlaxoSmithKline Inc.Flovent (fluticasone propionate) package insert. Research Triangle Park NC;2004."},{"key":"e_1_2_1_144_2","unstructured":"AstraZenecaLP.Rhinocort Aqua (budesonide) package insert. Wilmington DE;2005."},{"key":"e_1_2_1_145_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.110772"},{"key":"e_1_2_1_146_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000095343.32154.1d"},{"key":"e_1_2_1_147_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.42"},{"key":"e_1_2_1_148_2","first-page":"157","volume-title":"The top 100 drug interactions: a guide to patient management","author":"Hansten PD","year":"2004"},{"key":"e_1_2_1_149_2","unstructured":"Bristol\u2010Myers Squibb Company.Glucophage (metformin hydrochloride) package insert. Princeton NJ;2004."},{"key":"e_1_2_1_150_2","unstructured":"Bayer Pharmaceuticals Corporation.Precose (acarbose) package insert. West Haven CT;2004."},{"key":"e_1_2_1_151_2","unstructured":"Pfizer Inc.Glyset (miglitol) package insert. New York NY;2006."},{"key":"e_1_2_1_152_2","unstructured":"Pfizer Inc.Viagra (sildenafil) package insert. New York NY;2005."},{"key":"e_1_2_1_153_2","unstructured":"Bayer Healthcare.Levitra (vardenafil) package insert. West Haven CT;2005."},{"key":"e_1_2_1_154_2","unstructured":"Eli Lilly and Company.Cialis (tadalafil) package insert. Indianapolis IN;2005."},{"key":"e_1_2_1_155_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.13.1110.38091"},{"key":"e_1_2_1_156_2","doi-asserted-by":"publisher","DOI":"10.1086\/376907"},{"key":"e_1_2_1_157_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.3.481"},{"key":"e_1_2_1_158_2","unstructured":"SaboJP MachaS OksalaC et al.Stereoselective pharmacokinetics (PK) of methadone after coadministration with steady\u2010state tipranavir\/ritonavir 500\/200 mg bid (TPV\/r) in healthy volunteers [abstract]. Presented at the 7th international workshop on clinical pharmacology of HIV therapy Lisbon Portugal April 2022 2006;abstract 42."},{"key":"e_1_2_1_159_2","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0022-3565(24)29586-0","article-title":"Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist","volume":"297","author":"Huang P","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_160_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-199705000-00022"},{"key":"e_1_2_1_161_2","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0090-9556(25)06586-9","article-title":"Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism","volume":"23","author":"Labroo RB","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_162_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199909000-00020"},{"key":"e_1_2_1_163_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1998.tb03830.x"},{"key":"e_1_2_1_164_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.02002.x"},{"key":"e_1_2_1_165_2","doi-asserted-by":"publisher","DOI":"10.1177\/0310057X0002800602"},{"key":"e_1_2_1_166_2","doi-asserted-by":"publisher","DOI":"10.1080\/0049825021000017911"},{"key":"e_1_2_1_167_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2002.01177.x"},{"key":"e_1_2_1_168_2","first-page":"69","article-title":"Modulation of morphine\u20106\u2010glucuronide penetration into the brain by P\u2010glycoprotein","volume":"36","author":"Huwyler J","year":"1998","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_1_169_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1996.tb15619.x"},{"key":"e_1_2_1_170_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.5.725"},{"key":"e_1_2_1_171_2","unstructured":"Eli Lilly and Company.Prozac (fluoxetine hydrochloride) prescribing information. Indianapolis IN;2005."},{"key":"e_1_2_1_172_2","unstructured":"Pfizer Inc.Zoloft (sertraline hydrochloride) prescribing information. New York NY;2005."},{"key":"e_1_2_1_173_2","unstructured":"GlaxoSmithKline.Paxil (paroxetine hydrochloride) prescribing information. Philadelphia PA;2005."},{"key":"e_1_2_1_174_2","doi-asserted-by":"publisher","DOI":"10.1310\/5E7Q-PGWB-16UE-J48U"},{"key":"e_1_2_1_175_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00110a012"},{"key":"e_1_2_1_176_2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0090-9556(25)08637-4","article-title":"Identification of the rabbit and human cytochromes P\u2010450IIIA as the major enzymes involved in the N\u2010demethylation of diltiazem","volume":"18","author":"Pichard L","year":"1990","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_177_2","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0022-3565(24)35013-X","article-title":"Diltiazem inhibition of cytochrome P\u2010450 3A activity is due to metabolite intermediate complex formation","volume":"290","author":"Jones DR","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_178_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.65.5.998"},{"key":"e_1_2_1_179_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00169164"},{"key":"e_1_2_1_180_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.04.005"},{"key":"e_1_2_1_181_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199810000-00001"},{"key":"e_1_2_1_182_2","unstructured":"YehR GaverV ParkJ et al.Lopinavir\/ritonavir induces CYP2C9 and 2C19 activity as measured by warfarin and omeprazole biomarkers in healthy human volunteers [abstract]. Presented at the 5th international workshop on clinical pharmacology of HIV therapy Rome Italy April 13 2004: abstract 4.1."},{"key":"e_1_2_1_183_2","unstructured":"RyanCT.New black box warning for ritonavir\u2010boosted tipranavir [letter].AIDS Clin Care2006;4."},{"key":"e_1_2_1_184_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.10.1892"},{"key":"e_1_2_1_185_2","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.1998.03.414"},{"key":"e_1_2_1_186_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1990.00530060048015"},{"key":"e_1_2_1_187_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(89)80693-X"},{"key":"e_1_2_1_188_2","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1124\/dmd.105.004861","article-title":"Pathways of carbamazepine bioactivation in vitro. II. The role of human cytochrome P450 enzymes in the formation of 2\u2010hydroxyiminostilbene","volume":"33","author":"Pearce RE","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_189_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.11.1170"},{"key":"e_1_2_1_190_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200012010-00022"},{"key":"e_1_2_1_191_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19211"},{"key":"e_1_2_1_192_2","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S0090-9556(24)15085-4","article-title":"Formation of a dihydroxy metabolite of phenytoin in human liver microsomes\/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4","volume":"28","author":"Komatsu T","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_193_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600840305"},{"key":"e_1_2_1_194_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200408150-00006"},{"key":"e_1_2_1_195_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.01474.x"},{"key":"e_1_2_1_196_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.11.4328-4331.2004"},{"key":"e_1_2_1_197_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199141060-00007"},{"key":"e_1_2_1_198_2","unstructured":"Ortho\u2010McNeil Pharmaceuticals.Topamax (topiramate) package insert. Raritan NJ;2003."},{"key":"e_1_2_1_199_2","unstructured":"Elan Pharmaceuticals.Zonegran (zonisamide) package insert. San Diego CA;2002."},{"key":"e_1_2_1_200_2","unstructured":"Wallace Pharmaceuticals.Felbatol (felbamate) package insert. Goa India;2002."},{"key":"e_1_2_1_201_2","unstructured":"Cephalon Pharmaceuticals.Gabitril (tiagabine) package insert. West Chester PA;2005."},{"key":"e_1_2_1_202_2","unstructured":"UCB Pharma.Keppra (levetiracetam) package insert. Smyrna GA;2002."},{"key":"e_1_2_1_203_2","unstructured":"GlaxoSmithKline.Lamictal (lamotrigine) package insert. Research Triangle Park NC;2003."},{"key":"e_1_2_1_204_2","unstructured":"Pfizer.Neurontin (gabapentin) package insert. New York NY;2004."},{"key":"e_1_2_1_205_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.11.1500"},{"key":"e_1_2_1_206_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.002485"},{"key":"e_1_2_1_207_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.01516.x"},{"key":"e_1_2_1_208_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05712-8"},{"key":"e_1_2_1_209_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.1995.7.2.126"},{"key":"e_1_2_1_210_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000160518.12957.c0"},{"key":"e_1_2_1_211_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.4.511"},{"key":"e_1_2_1_212_2","doi-asserted-by":"publisher","DOI":"10.1159\/000135996"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.27.6.888","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.27.6.888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:05:18Z","timestamp":1761051918000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.27.6.888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":211,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["10.1592\/phco.27.6.888"],"URL":"https:\/\/doi.org\/10.1592\/phco.27.6.888","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}